Shanghai Haihe Biopharma Co. Ltd. has disclosed hydroxamic acid compounds acting as ENPP1 inhibitors reported to be useful for the treatment of cancer and infections.
Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.
Researchers from Yeungnam University and collaborators presented the discovery and preclinical evaluation of novel 7-azaoxindole derivatives for their antitumor activity.
Helicobacter pylori infection and germline genetic variants interacted with each other to affect the risk of gastric cancer in a study comparing more than 11,000 patients with stomach cancer and 44,000 people without cancer. Researchers from the RIKEN Center for Integrative Medical Sciences (IMS) published those findings in the March 30, 2023, issue of the New England Journal of Medicine.
Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.
Black Diamond Therapeutics Inc. has synthesized quinoline derivatives acting as Raf kinase B (B-Raf) mutant inhibitors reported to be useful for the treatment of cancer.
Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation (double mutant) in non-small-cell lung cancer (NSCLC).
RSS
